Market research
LOGC Contextlogic Inc
OTCQB USD Consumer Cyclical
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 519M
- P/E ratio
- Not available
- Analyst target
- 5.9
- Dividend yield
- Not available
- Beta
- 2.07
Community
Investor discussion
1 comment
Sign in to join the LOGC discussion.
5 years, 4 months ago
LogicBio Therapeutics, Inc is currently in a long term downtrend where the price is trading 38.2% below its 200 day moving average.
From a valuation standpoint, the stock is 96.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 52.6.
LogicBio Therapeutics, Inc's total revenue rose by inf% to $542K since the same quarter in the previous year.
Its net income has increased by 39.8% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 36.7% to $-8M since the same quarter in the previous year.
Based on the above factors, LogicBio Therapeutics, Inc gets an overall score of 4/5.